With the outbreak of COVID-19 in 2020, the demand for nucleic acid testing has grown rapidly. Medical institutions and disease control agencies across the country quickly implemented relevant national requirements to carry out nucleic acid testing for COVID-19, which played an important role in epidemic prevention and control. On October 25, 2021, the State Council issued the "Notice on Further Strengthening the Current New Coronavirus Nucleic Acid Testing Services" requiring that all general hospitals at level II and above, infectious disease specialist hospitals, and disease control institutions at all levels, etc. Report nucleic acid test results within 2019, and encourage the provision of new coronavirus nucleic acid rapid test reagents and supporting equipment based on the amount of testing to reduce waiting time. MRA-CDS-103 sample pretreatment system, this system can quickly complete all sample preparation before nucleic acid extraction, and can automatically complete the construction of PCR system, which is efficient and intelligent. The system integrates a large number of pretreatment steps that require manual operation into a closed negative pressure system, realizes the automation of sample pretreatment of "tube in and out", compatible with 5-30mL virus sampling tubes, supports single detection, 10 mixed 1, 20 Automatic open-top cup for mixing 1 sample. The system integrates multiple functions such as barcode scanning, sample shaking and mixing, lid opening/closing, sample transfer, proteinase K/internal control addition, negative and positive quality control addition, and template and PCR mix addition after nucleic acid extraction. The visual touch screen is easy to operate, flexible and convenient for process settings, and supports operation monitoring. The equipment has a built-in negative pressure filtration system and a UV sterilization system to avoid aerosol pollution, greatly reducing the probability of errors and biological risks, and is safe and reliable.